2016 Financial Calendar

Bagneux (France) – Genomic Vision (FR0011799907 – GV / PEA-PME eligible), a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing, today publishes its financial calendar for 2016. This preliminary agenda may be modified.

<table>
<thead>
<tr>
<th>Event</th>
<th>Date*</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015 Full-Year Results</td>
<td>Tuesday, March 22, 2016</td>
</tr>
<tr>
<td>Q1 2016 Revenue</td>
<td>Tuesday, May 10, 2016</td>
</tr>
<tr>
<td>Shareholders’ Meeting</td>
<td>Thursday, June 23, 2016</td>
</tr>
<tr>
<td>2016 Half-Year Results</td>
<td>Tuesday, July 26, 2016</td>
</tr>
<tr>
<td>Q3 2016 Revenue</td>
<td>Friday, October 28, 2016</td>
</tr>
</tbody>
</table>

* Press releases are distributed before the financial markets open.

ABOUT GENOMIC VISION
Founded in 2004, Genomic Vision is a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing. Using this innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. The Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHelix FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France. Genomic Vision has been listed on Compartment C of Euronext Paris since April 2014.

ABOUT MOLECULAR COMBING
DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if “combed”, and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient’s genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

For further information, please go to www.genomicvision.com
CONTACTS

Genomic Vision
Aaron Bensimon
Co-founder, Chairman & CEO
Tel.: +33 1 49 08 07 50
investisseurs@genomicvision.com

NewCap
Investor Relations / Strategic Communications
Dušan Orešanský / Emmanuel Huynh
Tel.: +33 1 44 71 94 92
gv@newcap.fr

Member of **CAC® Mid & Small, CAC® All- Tradable** and **EnterNext® PEA-PME 150** indexes